Nurix Therapeutics, Inc.
NRIX · FY2025 · Fiscal year ended Nov 30, 2025 · 10-K filed Jan 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $84.0M | $54.5M | +54.0% |
| Operating income | −$286M | −$213M | −34.1% |
| Net income | −$264M | −$194M | −36.6% |
Latest quarter: Q3 FY2026
Form 10-Q · Three months ended Aug 31, 2026 · filed Oct 13, 2026
| $ | Q3 FY2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $673M | $7.90M | +8,420% |
| Operating income | $560M | −$91.4M | |
| Net income | $550M | −$86.4M |
Q3 FY2026 dashboardQ3 FY2026 infographic
Questions
- What was Nurix Therapeutics's revenue in FY2025?
- $84.0M in FY2025 (Fiscal year ended Nov 30, 2025), +54.0% vs $54.5M a year earlier, per its 10-K filed Jan 2026.
- Was Nurix Therapeutics profitable in FY2025?
- No: net income was −$264M and operating income −$286M in FY2025.
- What was Nurix Therapeutics's revenue in Q3 FY2026?
- $673M (+8,420% vs a year earlier), per its Form 10-Q filed Oct 13, 2026.